

Discovery of Parkinson's disease states using machine learning and longitudinal data

Kristen A. Severson¹, Lana Chahine², Luba Smolensky³, Murtaza Dhuliawala¹,
Mark Frasier³, Kenney Ng¹, Soumya Ghosh¹, Jianying Hu¹

September 27, 2021

1. IBM Research, Center for Computational Health
2. University of Pittsburgh, Department of Neurology
3. Michael J. Fox Foundation

Why Machine Learning?

- Key challenges in PD


- Incomplete biological understanding
- Heterogeneity in symptom presentation and progression
- Desire for personalized patient management and prognostication
- Noisy, varied, and possibly qualitative measurements

- Key advantages of machine learning

- Ability to discover complex patterns
- Opportunity to incorporate prior knowledge
- Power to synthesize large amounts of data
- Possibility to incorporate uncertainty estimates

Disease progression modeling

IBM, Machine Learning



University of Pittsburgh, Neurology



Michael J. Fox Foundation, Advisory



Team:


Disease progression modeling

IBM, Machine Learning

University of Pittsburgh, Neurology

Michael J. Fox Foundation, Advisory

Team:



Disease progression modeling

IBM, Machine Learning





University of Pittsburgh, Neurology



Michael J. Fox Foundation, Advisory



Team:





Disease progression modeling

IBM, Machine Learning

University of Pittsburgh, Neurology

Michael J. Fox Foundation, Advisory

Team:





Disease progression modeling

IBM, Machine Learning


University of Pittsburgh, Neurology

Michael J. Fox Foundation, Advisory

Team:



Disease progression modeling



Patient management

Answer questions such as:

- How quickly will disease progress?
- What types of therapies will be most useful for me?
- When should I schedule my next visit?

Clinical trial design

Patient 1 ●

Patient 2 ●

Patient 4 ●

Past work

Expert opinion

Three subtypes:

- Postural instability and gait dominant
- Tremor dominant
- Indeterminant

3.10 GAIT
Instructions to examiner: Testing gait is best performed by having the patient walking away from and towards the examiner so that both right and left sides of the body can be easily observed.

3.11 FREEZING OF GAIT
Instructions to examiner: While assessing gait, also assess for the presence of any gait freezing.

3.12 POSTURAL STABILITY
Instructions to examiner: The test examines the response to sudden body displacement produced by a quick, forceful pull on the shoulders while the patient is standing erect with eyes open and feet comfortably apart and parallel to each other. Test retroposition. Stand behind the patient and instruct the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the observation of the number of retroposive steps. The first pull is an instructional demonstration and is purposely milder and not rated. The second time the shoulders are pulled briskly and forcefully towards the examiner with enough force to displace the center of gravity so that patient MUST take a step backwards. The examiner needs to be ready to catch the patient, but must stand sufficiently back so as to allow enough room for the patient to take several steps to recover independently. Do not allow the patient to flex the body abnormally forward in anticipation of the pull. Observe for the number of steps backwards or falling. Up to and including two steps for recovery is considered normal, so abnormal ratings begin with three steps. If the patient fails to understand the test, the examiner can repeat the test so that the rating is based on an assessment that the examiner feels reflects the patient's limitations rather than misunderstanding or lack of preparedness. Observe standing posture for item 3.13.

0: Normal: No problems. Recovers with one or two steps.
1: Slight: 3-5 steps, but subject recovers unaided.
2: Mild: More than 5 steps, but subject recovers unaided.
3: Moderate: Stands safely, but with absence of postural response; falls if not caught by examiner.
4: Severe: Very unstable, tends to lose balance spontaneously or with just a gentle pull on the shoulders.

3.16 KINETIC TREMOR OF THE HANDS
Instructions to examiner: This is tested by the finger-to-nose maneuver. With the arm starting from the outstretched position, the patient is instructed to touch the tip of the nose with the tip of the index finger. The patient is then instructed to return the hand to the outstretched position. The maximum amplitude of the tremor is noted. Rate only the maximum amplitude that is seen at any time as the final score.

3.17 REST TREMOR AMPLITUDE
Instructions to examiner: This and the next item have been placed purposefully at the end of the examination to allow the rater to gather observations on rest tremor that may appear at any time during the exam, including when quietly sitting, during walking, and during activities when some body parts are moving but others are at rest. Score the maximum amplitude that is seen at any time as the final score. Rate only the amplitude and not the persistence or the intermittency of the tremor.

Extremity ratings
0: Normal: No tremor.
1: Slight: < 1 cm in maximal amplitude.
2: Mild: ≥ 1 cm but < 3 cm in maximal amplitude.
3: Moderate: ≥ 3 cm but < 10 cm in maximal amplitude.
4: Severe: ≥ 10 cm in maximal amplitude.

Past work

Expert opinion

Three subtypes:

- Postural instability and gait dominant
- Tremor dominant
- Indeterminant

3.10 GAIT
 Instructions to examiner: Testing gait is best performed by having the patient walking away from and towards the examiner so that both right and left sides of the body can be easily observed.

3.11 FREEZING OF GAIT
 Instructions to examiner: While assessing gait, also assess for the presence of any gait freezing.

3.12 POSTURAL STABILITY
 Instructions to examiner: The test examines the response to sudden body displacement produced by a quick, forceful pull on the shoulders while the patient is standing erect with eyes open and feet comfortably apart and parallel to each other. Test retrogression. Stand behind the patient and instruct the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the observation of the number of retrogressive steps. The first pull is an instructional demonstration and is purposely milder and not rated. The second time the shoulders are pulled briskly and forcefully towards the examiner with enough force to displace the center of gravity so that patient MUST take a step backwards. The examiner needs to be ready to catch the patient, but must stand sufficiently back so as to allow enough room for the patient to take several steps to recover independently. Do not allow the patient to flex the body abnormally forward in anticipation of the pull. Observe for the number of steps backwards or falling. Up to and including two steps for recovery is considered normal, so abnormal ratings begin with three steps. If the patient fails to understand the test, the examiner can repeat the test so that the rating is based on an assessment that the examiner feels reflects the patient's limitations rather than misunderstanding or lack of preparedness. Observe standing posture for item 3.13.

0: Normal: No problems. Recovers with one or two steps.
 1: Slight: 3-5 steps, but subject recovers unaided.
 2: Mild: More than 5 steps, but subject recovers unaided.
 3: Moderate: Stands safely, but with absence of postural response; falls if not caught by examiner.
 4: Severe: Very unstable, tends to lose balance spontaneously or with just a gentle pull on the shoulders.

3.16 KINETIC TREMOR OF THE HANDS
 Instructions to examiner: This item receives one rating for all rest tremor and focuses on the constancy of rest tremor during the examination period when different body parts are variously at rest. It is rated purposefully at the end of the examination.

3.17 REST TREMOR AMPLITUDE
 Instructions to examiner: This and the next item have been placed purposefully at the end of the examination to allow the rater to gather observations on rest tremor that may appear at any time during the exam, including when quietly sitting, during walking, and during activities when some body parts are moving but others are at rest. Score the maximum amplitude that is seen at any time as the final score. Rate only the amplitude and not the persistence or the intermittency of the tremor. As part of this rating, the patient should sit quietly in a chair with the hands placed on the arms of the chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other directives. Rest tremor is assessed separately for all four limbs and also for the lip/jaw. Rate only the maximum amplitude that is seen at any time as the final rating.

Extremity ratings
 0: Normal: No tremor.
 1: Slight: < 1 cm in maximal amplitude.
 2: Mild: ≥ 1 cm but < 3 cm in maximal amplitude.
 3: Moderate: ≥ 3 cm but < 10 cm in maximal amplitude.
 4: Severe: ≥ 10 cm in maximal amplitude.

Machine-learning based approaches

Three subtypes:

- Mild motor-predominant
- Diffuse malignant
- Intermediate




Figure 1 Dendrogram of the final hierarchical cluster solution in the PPMI population. Green = mild motor-predominant; blue = intermediate; red = diffuse malignant.

Past work

Expert opinion

Three subtypes:

- Postural instability and gait dominant
- Tremor dominant
- Indeterminant

3.10 GAIT
 Instructions to examiner: Testing gait is best performed by having the patient walking away from and towards the examiner so that both right and left sides of the body can be easily observed.

3.11 FREEZING OF GAIT
 Instructions to examiner: While assessing gait, also assess for the presence of any gait freezing episodes.

3.12 POSTURAL STABILITY
 Instructions to examiner: The test examines the response to sudden body displacement produced by a quick, forceful pull on the shoulders while the patient is standing erect with eyes open and feet comfortably apart and parallel to each other. Test retrospection. Stand behind the patient and instruct the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the observation of the number of retrospective steps. The first pull is an instructional demonstration and is purposely milder and not rated. The second time the shoulders are pulled briskly and forcefully towards the examiner with enough force to displace the center of gravity so that patient MUST take a step backwards. The examiner needs to be ready to catch the patient, but must stand sufficiently back so as to allow enough room for the patient to take several steps to recover independently. Do not allow the patient to flex the body abnormally forward in anticipation of the pull. Observe for the number of steps backwards or falling. Up to and including two steps for recovery is considered normal, so abnormal ratings begin with three steps. If the patient fails to understand the test, the examiner can repeat the test so that the rating is based on an assessment that the examiner feels reflects the patient's limitations rather than misunderstanding or lack of preparedness. Observe standing posture for item 3.13.

0: Normal: No problems. Recovers with one or two steps.
 1: Slight: 3-5 steps, but subject recovers unaided.
 2: Mild: More than 5 steps, but subject recovers unaided.
 3: Moderate: Stands safely, but with absence of postural response; falls if not caught by examiner.
 4: Severe: Very unstable, tends to lose balance spontaneously or with just a gentle pull on the shoulders.

3.18 CONSTANCY OF REST TREMOR
 Instructions to examiner: This item receives one rating for all rest tremor and focuses on the constancy of rest tremor during the examination period when different body parts are variously at rest. It is rated purposefully.

3.15 POSTURAL TREMOR OF THE HANDS
 Instructions to examiner: All tremor, including re-emergent rest tremor, that is present in this posture is purposefully.

3.16 KINETIC TREMOR OF THE HANDS
 Instructions to examiner: This is tested by the finger-to-nose maneuver. With the arm starting from the outstretched position, the patient is instructed to touch the tip of the nose with the tip of the index finger.

3.17 REST TREMOR AMPLITUDE
 Instructions to examiner: This and the next item have been placed purposefully at the end of the examination to allow the rater to gather observations on rest tremor that may appear at any time during the exam, including when quietly sitting, during walking, and during activities when some body parts are moving but others are at rest. Score the maximum amplitude that is seen at any time as the final score. Rate only the amplitude and not the persistence or the intermittency of the tremor. As part of this rating, the patient should sit quietly in a chair with the hands placed on the arms of the chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other directives. Rest tremor is assessed separately for all four limbs and also for the lip/jaw. Rate only the maximum amplitude that is seen at any time as the final rating.

Extremity ratings
 0: Normal: No tremor.
 1: Slight: < 1 cm in maximal amplitude.
 2: Mild: ≥ 1 cm but < 3 cm in maximal amplitude.
 3: Moderate: ≥ 3 cm but < 10 cm in maximal amplitude.
 4: Severe: ≥ 10 cm in maximal amplitude.

Machine-learning based approaches

Four subtypes:

- Fast motor progression (1)
- Mild motor and non-motor disease (2)
- Severe motor disease, poor psychological well-being and sleep (3)
- Slow motor progression (4)




Figure 1 Important salient clinical features of the four clusters across the two cohorts where the percentages within each cluster are from the Tracking Parkinson's cohort.

Analysis Goals

Analysis Goals

- Particularly interested in discovering *disease states*

Analysis Goals

- Particularly interested in discovering *disease states*

Disease state definition: *discrete label* of a patient with two primary characteristics: a transition model which describes the probability of changing states and an observation model which describes the distribution of clinical measures associated with a state

Analysis Goals

- Particularly interested in discovering *disease states*
- Account for *medications* which affect clinical presentation but do not affect disease course

Analysis Goals

- Particularly interested in discovering *disease states*
- Account for *medications* which affect clinical presentation but do not affect disease course
- Allow for *personalized* deviations in symptom presentation and medication effects

Key Model Assumptions

Key Model Assumptions

- Pre-process the data using a latent variable model

Key Model Assumptions

- Pre-process the data using a latent variable model
- Model progression using a Markov model, a specific type of probabilistic model

Key Model Assumptions


- Pre-process the data using a latent variable model
- Model progression using a Markov model, a specific type of probabilistic model
- Medications effect symptoms but not underlying disease progression

Key Model Assumptions


- Pre-process the data using a latent variable model
- Model progression using a Markov model, a specific type of probabilistic model
- Medications effect symptoms but not underlying disease progression
- Patients can only move progressively through states

	To			
	1	2	3	4
1	Blue	Blue	Blue	Blue
2	White	Blue	Blue	Blue
3	White	White	Blue	Blue
4	White	White	White	Blue


Personalized input output hidden Markov models




Personalized input output hidden Markov models



Personalized input output hidden Markov models



Personalized input output hidden Markov models



Personalized input output hidden Markov models

- The graphical model on the previous slide is specified using the following distributions:

$$z_{i,1} \sim \text{Cat}(\pi), \quad z_{i,t} | z_{i,t-1} = j \sim \text{Cat}(A_j)$$

$$x_{i,t} | z_{i,t} = k, d_{i,t} \sim \mathcal{N}(\mu_k + r_i + (v_k + m_i)d_{i,t}, \Sigma_k)$$

$$m_i \sim \mathcal{N}(0, \sigma_m^2 \mathbf{I}_D), \quad r_i \sim \mathcal{N}(0, \sigma_r^2 \mathbf{I}_D), \quad v_k \sim \mathcal{N}(0, \sigma_v^2, \mathbf{I}_D)$$

Learning the model

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

Optimization objective:

$$\mathcal{L}(\theta, \lambda) = \mathbb{E}_{q(\mathbf{Z}, \mathbf{M}, \mathbf{R}|\mathbf{X}, \lambda)} [\log p(\mathbf{X}, \mathbf{Z}, \mathbf{M}, \mathbf{R}|\theta)] + \mathbb{H}[q(\mathbf{Z}, \mathbf{M}, \mathbf{R}|\mathbf{X}, \lambda)]$$

Two remaining pieces to the learning algorithm for PIOHMM:

1. How to choose $q(\mathbf{Z}, \mathbf{M}, \mathbf{R}|\mathbf{X}, \lambda)$?
2. Given the posterior approximation, can we evaluate the required expectations?

Choosing the variational approximation

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

- Need to specify $q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)$

Choosing the variational approximation

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

- Need to specify $q(\mathbf{Z}, \mathbf{M}, \mathbf{R}|\mathbf{X}, \lambda)$
- Mean field approximation


$$q(\mathbf{Z}, \mathbf{M}, \mathbf{R}|\mathbf{X}, \lambda) = \prod_{i=1}^N \left[q(m_i|\lambda_{m_i})q(r_i|\lambda_{r_i}) \prod_{t=1}^T q(z_{it}|\lambda_{z_{it}}) \right]$$

Choosing the variational approximation

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

- Need to specify $q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)$
- Mean field approximation

$$q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda) = \prod_{i=1}^N \left[q(m_i | \lambda_{m_i}) q(r_i | \lambda_{r_i}) \prod_{t=1}^T q(z_{it} | \lambda_{z_{it}}) \right]$$




Choosing the variational approximation

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

- Need to specify $q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)$
- Mean field approximation

$$q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda) = \prod_{i=1}^N \left[q(m_i | \lambda_{m_i}) q(r_i | \lambda_{r_i}) \prod_{t=1}^T q(z_{it} | \lambda_{z_{it}}) \right]$$

- Leverage structure of hidden states




Choosing the variational approximation

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

- Need to specify $q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)$
- Mean field approximation

$$q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda) = \prod_{i=1}^N \left[q(m_i | \lambda_{m_i}) q(r_i | \lambda_{r_i}) \prod_{t=1}^T q(z_{it} | \lambda_{z_{it}}) \right]$$



- Leverage structure of hidden states

$$q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda) = \prod_{i=1}^N \left[q(m_i | \lambda_{m_i}) q(r_i | \lambda_{r_i}) q(z_{i1} | r_i, m_i, x_i) \prod_{t=2}^T q(z_{it} | z_{i(t-1)}, r_i, m_i, x_i) \right]$$

Evaluating the expectations

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

Optimization objective:

$$\mathcal{L}(\theta, \lambda) = \mathbb{E}_{q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)} [\log p(\mathbf{X}, \mathbf{Z}, \mathbf{M}, \mathbf{R} | \theta)] + \mathbb{H}[q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)]$$

Evaluating the expectations

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

Optimization objective:

$$\mathcal{L}(\theta, \lambda) = \mathbb{E}_{q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)} [\log p(\mathbf{X}, \mathbf{Z}, \mathbf{M}, \mathbf{R} | \theta)] + \mathbb{H}[q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)]$$

$$\mathbb{E}_{q(z_i, m_i, r_i | x_i, \lambda)} [\log p(x_i | z_i, m_i, r_i, \theta)]$$

Evaluating the expectations

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

Optimization objective:

$$\mathcal{L}(\theta, \lambda) = \mathbb{E}_{q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)} [\log p(\mathbf{X}, \mathbf{Z}, \mathbf{M}, \mathbf{R} | \theta)] + \mathbb{H}[q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)]$$

Monte Carlo approximation:

$$\mathbb{E}_{q(z_i, m_i, r_i | x_i, \lambda)} [\log p(x_i | z_i, m_i, r_i, \theta)] \approx \frac{1}{S} \sum_{s=1}^S \mathbb{E}_{q(z_i | x_i, m_i = m_i^s, r_i = r_i^s)} [\log p(x_i | z_i, m_i = m_i^s, r_i = r_i^s, \theta)]$$

Evaluating the expectations

X: Observed data
Z: Disease states
R: Personalized state
M: Personalized medication effects

Optimization objective:

$$\mathcal{L}(\theta, \lambda) = \mathbb{E}_{q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)} [\log p(\mathbf{X}, \mathbf{Z}, \mathbf{M}, \mathbf{R} | \theta)] + \mathbb{H}[q(\mathbf{Z}, \mathbf{M}, \mathbf{R} | \mathbf{X}, \lambda)]$$

Monte Carlo approximation:

$$\mathbb{E}_{q(z_i, m_i, r_i | x_i, \lambda)} [\log p(x_i | z_i, m_i, r_i, \theta)] \approx \frac{1}{S} \sum_{s=1}^S \mathbb{E}_{q(z_i | x_i, m_i = m_i^s, r_i = r_i^s)} [\log p(x_i | z_i, m_i = m_i^s, r_i = r_i^s, \theta)]$$

“Reparameterization trick”:


$$\epsilon_{m_i}^s \sim \mathcal{N}(\mathbf{0}, \mathbf{I})$$

$$m_i^s = \hat{L}_{m_i} \epsilon_{m_i}^s + \hat{\mu}_{m_i}$$



$$\epsilon_{r_i}^s \sim \mathcal{N}(\mathbf{0}, \mathbf{I})$$

$$r_i^s = \hat{L}_{r_i} \epsilon_{r_i}^s + \hat{\mu}_{r_i}$$

Synthetic proof of concept




Summarizing the project




Dataset for analysis

- Longitudinal data from the Parkinson's Progression Markers Initiative (PPMI) and Parkinson's Disease Biomarker Program (PDBP)
- 82 variables measuring motor and non-motor symptoms over time
- 423 PD patients from PPMI and 610 PD patients from PDBP



Analysis workflow



Key take-aways

- The learning procedure resulted in an 8 state model where states are primarily differentiated by functional impairment, tremor, bradykinesia, and neuropsychiatric measures

Key take-aways


- The learning procedure resulted in an 8 state model where states are primarily differentiated by functional impairment, tremor, bradykinesia, and neuropsychiatric measures
- The predictive model discovers non-sequential overlapping disease progression trajectories

Key take-aways

- The learning procedure resulted in an 8 state model where states are primarily differentiated by functional impairment, tremor, bradykinesia, and neuropsychiatric measures
- The predictive model discovers non-sequential overlapping disease progression trajectories
- The addition of personalized medication effects leads to a more descriptive model

Model parameters – State means


How can we interpret the states?



Severson et al. Discovery of Parkinson's disease states using machine learning and longitudinal data. *Lancet Digital Health*. 2021.

Model parameters – State means


How can we interpret the states?



Severson et al. Discovery of Parkinson's disease states using machine learning and longitudinal data. *Lancet Digital Health*. 2021.

Model parameters – State means


How can we interpret the states?



Severson et al. Discovery of Parkinson’s disease states using machine learning and longitudinal data. *Lancet Digital Health*. 2021.


Outcome measures

What are the clinical implications of the states?



Progression pathways

What can we say about the progression of the states?



Predictive capability

- What can we say about the predictive capability of the model?
- Predictive question: how well can we predict disease state at year 2 given data from baseline?
- Prediction in this case is defined as the most probable state assignment

PPMI Testing	Condition Positive	Condition Negative	
Predicted Positive	10	7	Precision = 0.59
Predicted Negative	14	52	NPV = 0.79
	Recall = 0.42	Specificity = 0.88	Accuracy = 0.75 F1 Score = 0.49

PDBP	Condition Positive	Condition Negative	
Predicted Positive	91	62	Precision = 0.59
Predicted Negative	52	405	NPV = 0.87
	Recall = 0.64	Specificity = 0.87	Accuracy = 0.81 F1 Score = 0.61

Conclusions

- Application of the disease progression resulted in novel Parkinson's disease insights and strong predictive performance
- Disease state was found to vary across motor and non-motor symptoms
- The model discovered non-sequential, overlapping disease progression trajectories, supporting the use of non-deterministic disease progression models

Acknowledgements

Project team

IBM, Machine Learning




Kristen Severson



Soumya Ghosh



Jianying Hu



Murtaza Dhuliawala



Kenney Ng

University of Pittsburgh, Neurology



Lana Chahine

Michael J. Fox Foundation, Advisory



Mark Frasier



Luba Smolensky

Funding provided by the Michael J. Fox Foundation



Comparison to a standard hidden Markov model

